Vinblastine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | VELBAN | — | 1965-11-25 | fda.gov ↗ |
Trials 153 · started per year
Also used as a comparator or background therapy in 56 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT01056679 Background | Apr 2010 → Apr 2014 | Hodgkins lymphoma | University of Cologne | Completed | No outcome recorded |
| Phase 1 | NCT01060904 Background | Jan 2010 → Sep 2012 | Hodgkins lymphoma | Seagen Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00498979 Background | May 2007 → May 2010 | melanoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00006212 Background | Nov 1999 → ? | lung cancer | Center for Molecular Medicine | Unknown | No outcome recorded |
| Phase 1 | NCT00002887 Background | Jul 1995 → ? | lung cancer | Ottawa Regional Cancer Centre | Unknown | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03549715 Background | Dec 2018 → Jun 2024 | infiltrating bladder urothelial carcinoma | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | Unknown | No outcome recorded |
| Phase 1/2 | NCT02979522 Background | Sep 2017 → May 2020 overdue | classic Hodgkin lymphoma | Takeda | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03033914 Background | Jan 2017 → Jan 2027 expected | classic Hodgkin lymphoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 228 trials | ||||||
| Phase 2 | NCT06424899 Background | May 2024 → May 2027 expected | non-small cell lung carcinoma | Zeng Jian | Recruiting | No outcome recorded |
| Phase 2 | NCT05627115 Background | Mar 2024 → Oct 2028 expected | Hodgkins lymphoma | University College, London | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05772624 Background | Feb 2023 → Mar 2024 | — | Hospital Universitario Dr. Jose E. Gonzalez | Unknown | No outcome recorded |
| Phase 2 | NCT05180825 Comparator | May 2022 → Nov 2031 expected | mixed neuronal-glial tumor, pleomorphic xanthoastrocytoma | University Hospital, Strasbourg, France | Recruiting | No outcome recorded |
| Phase 2 | NCT05253495 Background | Feb 2022 → Dec 2027 expected | Hodgkins lymphoma, non-Hodgkin lymphoma | New York Medical College | Recruiting | No outcome recorded |
| Phase 2 | NCT05137262 Background | Oct 2021 → Aug 2026 overdue | urinary bladder cancer, urothelial carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03472274 Comparator | Oct 2018 → Apr 2021 | urinary bladder cancer | CRIS Cancer Foundation | Completed | No outcome recorded |
| Phase 2 | NCT03407144 Background | Apr 2018 → Nov 2026 expected | classic Hodgkin lymphoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03527628 Background | Jan 2018 → Jan 2021 | classic Hodgkin lymphoma | King Abdullah International Medical Research Center | Unknown | No outcome recorded |
| Phase 2 | NCT02641314 Background | Dec 2016 → Jun 2023 | neuroblastoma | University of Cologne | Completed | No outcome recorded |
| Phase 2 | NCT02710734 Background | Feb 2016 → Nov 2025 | urothelial carcinoma | Fox Chase Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02414568 Background | Jul 2015 → Dec 2018 | classic Hodgkin lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 2 | NCT02292979 Background | Mar 2015 → Dec 2016 | Hodgkins lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 2 | NCT02181738 Background | Aug 2014 → Aug 2017 | Hodgkins lymphoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT02299999 Comparator | Apr 2014 → Dec 2022 overdue | breast cancer | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01700946 Comparator | Apr 2013 → Jul 2021 | B-cell childhood acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02275598 Background | Apr → Nov 2013 | Hodgkins lymphoma | University of Modena and Reggio Emilia | Unknown | No outcome recorded |
| Phase 2 | NCT01876082 Comparator | Sep 2012 → Mar 2018 | desmoid tumor | Institut Bergonié | Completed | No outcome recorded |
| Phase 2 | NCT01534078 Background | Mar 2012 → Jan 2015 | Hodgkins lymphoma | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00797472 Comparator | Jul 2011 → Apr 2014 | Hodgkins lymphoma | American Scitech International | Unknown | No outcome recorded |
| Phase 2 | NCT00822120 Comparator | Jul 2009 → Apr 2016 | lymphoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00512980 Comparator | Aug 2008 → Nov 2013 | Hodgkins lymphoma | University of Cologne | Terminated | No outcome recorded |
| Phase 2 | NCT00654732 Background | Mar 2008 → Sep 2018 | classic Hodgkin lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00520403 Background | Sep 2007 → Mar 2010 | renal cell carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00352027 Background | Jul 2006 → May 2015 | Hodgkins lymphoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00083083 Background | Mar 2005 → Jun 2006 | lung cancer | American College of Radiology Imaging Network | Unknown | No outcome recorded |
| Phase 2 | NCT00079105 Comparator | Jan 2004 → Dec 2010 | lymphoma | Newcastle-upon-Tyne Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 2 | NCT01404936 Background | Jul 1996 → Dec 2011 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02205762 Background | Nov 2016 → Jul 2026 overdue | Langerhans cell histiocytosis | North American Consortium for Histiocytosis | Active not recruiting | No outcome recorded |
| Phase 315 trials | ||||||
| Phase 3 | NCT00488605 Comparator | Aug 2023 | leukemia | University of New Mexico | Withdrawn | No outcome recorded |
| Phase 3 | NCT05566795 Comparator | Feb 2023 → Jun 2027 expected | childhood low-grade glioma | Day One Biopharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03907488 Background | Aug 2019 → Mar 2024 overdue | Hodgkin's lymphoma, lymphocytic depletion, Hodgkin's lymphoma, mixed cellularity, nodular sclerosis classical Hodgkin lymphoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03479918 Comparator | Mar 2018 → Mar 2021 | high grade B-cell lymphoma | Elena N.Parovichnikova | Unknown | No outcome recorded |
| Phase 3 | NCT02670707 Comparator | Mar 2016 → Jan 2027 expected | Langerhans cell histiocytosis | Baylor College of Medicine | Recruiting | No outcome recorded |
| Phase 3 | NCT01812369 Comparator | Feb 2013 → Sep 2023 | urinary bladder cancer | University Hospital, Rouen | Completed | No outcome recorded |
| Phase 3 | NCT01712490 Background | Nov 2012 → Apr 2017 | Hodgkins lymphoma | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01356680 Background | Jan 2012 → Mar 2020 | Hodgkins lymphoma | University of Cologne | Completed | No outcome recorded |
| Phase 3 | NCT00816959 Comparator | Jul 2011 → Apr 2014 | Hodgkins lymphoma | American Scitech International | Unknown | No outcome recorded |
| Phase 3 | NCT02818725 Background | Jun 2010 → Sep 2016 | infiltrating urothelial carcinoma | UNICANCER | Completed | No outcome recorded |
| Phase 3 | NCT00678327 Comparator | Aug 2008 → Jan 2016 | lymphoma | University College, London | Completed | No outcome recorded |
| Phase 3 | NCT00049595 Comparator | Aug 2002 → Jan 2010 | lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 3 | NCT00038558 Background | Nov 2001 → Feb 2004 | Hodgkins lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT01251107 Comparator | Mar 2000 → Nov 2009 | Hodgkins lymphoma | Fondazione Michelangelo | Completed | No outcome recorded |
| Phase 3 | NCT00002561 Comparator | Jan 1994 → Aug 2011 | Hodgkins lymphoma | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06831370 Background | Aug 2024 → Mar 2028 expected | Hodgkins lymphoma | Takeda | Recruiting | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07202819 Comparator | Sep 2025 → May 2026 overdue | urinary bladder carcinoma | Assiut University | Recruiting | No outcome recorded |
| — | NCT06081400 Comparator | Mar 2024 → Mar 2027 expected | desmoid tumor | University Hospital, Strasbourg, France | Recruiting | No outcome recorded |
| — | NCT07171827 Background | Mar 2023 → Feb 2025 | classic Hodgkin lymphoma | Helwan University | Completed | No outcome recorded |
Evidence & citations 21 cited values
Every value below carries the sentence it was read from. 210 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vinblastine | “Temozolamide 150mg/m2 x4, cisplatin 20mg/m2 x 4, vinblastine 1.2mg/m2 x 4, bevacizumab 7.5-15 mg/kg x 1, interferon 5mg/m2 x5 and aldesleukin 36,18,9, % 9 miu/day over 4 days...” NCT01743157 ↗193“OBJECTIVE: To evaluate the efficacy of 4 cycles of vinblastine, Adriamycin (doxorubicin), methotrexate, and prednisone (VAMP) in patients with favorable-risk Hodgkin lymphoma...” PMID 22735430 ↗ Jun 2012 “INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also...” NCT04781725 ↗ “Chemotherapy is based upon regimes with well known effectiveness in Hodgkin lymphoma. (i.e. ABVD: doxorubicin, bleomycin, vinblastine and dacarbazine and ESHAP: Etoposide,...” NCT03500133 ↗ “Standard neoadjuvant chemotherapy for muscle-invasive bladder cancer, typically consisting of cisplatin-based regimens such as MVAC (methotrexate, vinblastine, doxorubicin, and...” NCT07202819 ↗ “The other drug must contain one of the following: etoposide, vinorelbine, vinblastine, pemetrexed, taxanes (e.g., paclitaxel, docetaxel, albumin paclitaxel, paclitaxel...” NCT06424899 ↗ “MVAC regimen: Methotrexate (30 mg/m2 IV bolus, D1, 15, 22), Vinblastine (3 mg/m2 IV bolus, D2, 15, 22), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), every 4 weeks” NCT03296306 ↗ “The other half (Group II) will receive a combination of intravenous Adriamycin, Bleomycin, Vinblastine and Dacarbazine every other week for 12 treatments.” NCT00797472 ↗ “ABVD was given every 28 days (doxorubicin 25 mg/m2, bleomycin 10 mg/m2, vinblastine 6 mg/m2, and dacarbazine 375 mg/m2 intravenously on days 1 and 15)” PMID 30658935 ↗ Jan 2019 “DD-MVAC consists of Methotrexate 30 mg/m2 iv day 1, Vinblastine 3 mg/m2 iv day 2, Cisplatin 70 mg/m2 iv day 2 and Doxorubicin 30 mg/m2 iv day 2.” NCT03674424 ↗ “Doxorubicin 25 mg/m2 IV, Bleomycin 10,000 units/m2 IV, Vinblastine 6 mg/m2 IV, Dacarbazine 375 mg/m2 IV on days 1-15 of each 28 day cycle.” NCT02275598 ↗ “Vinblastine 3 mg/m2xd i.v. (maximum total daily dose: 6 mg) administered day 1 and 15 (every two weeks) as single daily dose” NCT02641314 ↗ “methotrexate 30mg/m² + vinblastine 6mg/m² (IV infusion) once/week for 6 months, then every other week from months 7 to 12” NCT06081400 ↗ “Adriamycin 25 mg/m2 bleomycin 10 units/m2 vinblastine 6 mg/m2 dacarbazine 375 mg/m on Days 1 and 15 of each 28 day cycle” NCT00901303 ↗ “Standard AMVAC dose is as follows: methotrexate 30mg/m2, vinblastine 3mg/m2, doxorubicin 30mg/m2, and cisplatin 70mg/m2.” NCT04506554 ↗ “Participants will receive orally administered mirdametinib in combination with intravenous vinblastine chemotherapy” NCT06666348 ↗ “Patients receive doxorubicin hydrochloride intravenously (IV) and vinblastine IV on day 1 of weeks 1, 3, 5, and 7” NCT00846742 ↗ “Methotrexate (30 mg /m²) and Vinblastine 3 (mg /m²) day 1; Adriamycin 30 mg /m² and Cisplatin 70 mg /m² in day2” NCT02969083 ↗ “doxorubicin 25 mg/m\^2 IV bleomycin 10 units/m\^2 IV vinblastine 6 mg/m\^2 IV dacarbazine 375 mg/m\^2 IV” NCT01118026 ↗ “doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)-based response-adapted therapy” NCT01652261 ↗ “Vinblastine, IV, 3mg/m², once a week (except during radiotherapy: 1mg/m², 3 times a week)” NCT03011528 ↗ “brentuximab vedotin x 2; doxorubicin x 2; vinblastine x 2; dacarbazine 2x; rituximab x 2” NCT05253495 ↗ “Vinblastine - 6mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.” NCT01578967 ↗ “* Dose Dense Methotrexate - Vinblastine - Adriamycin - Cisplatin (MVAC)” NCT06290687 ↗ “Vinblastine will be given IV (into a vein) one day a week for 6 weeks.” NCT00488605 ↗ “Vinblastine6 mg/m2 iv days 1,15 Dacarbazine375mg/m2 iv days 1,15” NCT00795613 ↗ “Vinblastine 3 mg/m2 Slow IV push or infusion over Day 1” NCT01031420 ↗ “Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine)” NCT02299999 ↗ “Vinblastine 6 mg/m2 (no more than 10 mg) in D 1 and 15” NCT07234487 ↗ “use other vinblastine drugs with the same mechanism” NCT06486337 ↗ “Adriamycin, Bleomycin, Vinblastine and Dacarbazine” NCT00816959 ↗ “Doxorubicin, Vinblastine, and Dacarbazine - AVD” NCT05627115 ↗ “Vinblastine: 1.5mg/m\^2, daily, IV, days 1-4” NCT00673361 ↗ “Vinblastine 3mg/m2 intravenously on day 2” NCT03472274 ↗ “Vinblastine 6 mg/m2 i.v. day 1 and 15” NCT00433433 ↗ “Vinblastine 6 mg/m2 i.v. day 1 and 15” NCT00784537 ↗ “Vemurafenib, Vinblastine, Vincristine” NCT02788201 ↗ “Vinblastine 6 mg/mq i.v. day 1 and 15” NCT01523847 ↗ “Vinblastine 6 mg/m2 i.v. day 1 and 8” NCT02247869 ↗ “Vinblastine, 3 mg/m2 IV bolus, Day2” NCT04047693 ↗ “VINBLASTINE: 3 mg/m² on day 2” NCT02818725 ↗ “Vinblastine 5 mg/m2 IV day 1” NCT03479918 ↗ “2. Vinblastine 3 mg/m2 IV D1” NCT03549715 ↗ “vinblastine (VBL) regimen” NCT05566795 ↗ “Velban(R) (vinblastine)” NCT00602667 ↗ “vinblastine 10 mg/m2/D” NCT00970385 ↗ “Vinblastine” NCT01468740 ↗ “Vinblastine” NCT00592111 ↗ |
| Known as | 29060-LE | ChEMBL registry synonym — accepted as the source's own label CHEMBL159 ↗ |
| Known as | [3h]-vinblastine | ChEMBL registry synonym — accepted as the source's own label CHEMBL159 ↗ |
| Known as | Alkaban-aq | ChEMBL registry synonym — accepted as the source's own label CHEMBL159 ↗ |
| Known as | NSC-47842 | ChEMBL registry synonym — accepted as the source's own label CHEMBL159 ↗ |
| Known as | NSC-49842 | “Vinblastine, VBL, NSC-49842; followed by subtotal nodal irradiation as in Arm I.” NCT00002495 ↗1“Vinblastine, VBL, NSC-49842” NCT00002462 ↗ |
| Known as | VBL | “Vinblastine, VBL, NSC-49842; followed by subtotal nodal irradiation as in Arm I.” NCT00002495 ↗3“single-drug vinBLAStine (VBL)” NCT07013565 ↗ “Vinblastine, VBL, NSC-49842” NCT00002462 ↗ “VBL” NCT05566795 ↗ |
| Known as | Velban | “Vinblastine (Velban)” NCT07013565 ↗ |
| Known as | Velban(R) (vinblastine) | “Velban(R) (vinblastine)” NCT00602667 ↗ |
| Known as | Velbe | “weekly intra-venous Vinblastine (Velbe©) during 18 courses of 4 weeks each” NCT05180825 ↗ |
| Known as | Vinblast,lederle | ChEMBL registry synonym — accepted as the source's own label CHEMBL159 ↗ |
| Known as | Vinblastina | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01067690 ↗ |
| Known as | vinblastine sulfate | “Treatment with VEPEMB - Vinblastine sulfate, Cyclophosphamide, Procarbazine hydrochloride, Prednisolone, Etoposide, Mitoxantrone hydrochloride, and Bleomycin sulfate” NCT00079105 ↗16“Patients receive vinblastine sulfate (5 mg/m2) IV and methotrexate (30 mg/m2) IV weekly for 26 weeks, then every 2 weeks for an additional 26 weeks.” NCT00003019 ↗ “AVD (adriamycin,vinblastine sulfate and dacarbazine)” NCT05772624 ↗ “Drug: vinblastine sulfate” NCT00049595 ↗ “Drug: vinblastine sulfate” NCT00678327 ↗ “Drug: vinblastine sulfate” NCT00028756 ↗ “vinblastine sulfate” NCT00014274 ↗ |
| Known as | Vinblastine Sulphate | “Vinblastine Sulphate chemotherapy via intravenous administration once a week.” NCT00575796 ↗ |
| Known as | vinblastine sulphate injection | “Drug: vinblastine sulphate injection” NCT00213278 ↗ |
| Known as | Vinblastini sulfas | ChEMBL registry synonym — accepted as the source's own label CHEMBL159 ↗ |
| Known as | Vincaleukoblastine sulfate | ChEMBL registry synonym — accepted as the source's own label CHEMBL159 ↗ |
| Known as | Vlb monosulfate | ChEMBL registry synonym — accepted as the source's own label CHEMBL159 ↗ |
| Action | Inhibit | “Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine, work in different ways to stop the growth of tumor cells” NCT00654732 ↗ |
| Modality | Small molecule | “the vinca alkaloid vinblastine” NCT00061893 ↗ |
| Route | Intravenous | “A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer” NCT00001570 ↗ |